Japan Drug Makers See Need To Catch Up In Biotechs
This article was originally published in PharmAsia News
Executive Summary
Japanese drug makers are attempting to catch up to their major rivals abroad by stepping up efforts to bring antibody and other bioengineered pharmaceuticals to market. U.S. and European companies have dominated the market for biotech drugs, but Takeda and other drug makers hope to close the gap. Takeda has applications pending in Japan for an antibody drug, while Eisai and Chugai market theirs, but they and other Japanese drug makers continue to lag. The smaller share of the world market usually means the drug makers also spend less on research. (Click here for more - a subscription may be required
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.